Co-Packaged HIV Drug User Fees Likely To Be Waived By AIDS Relief Plan
Executive Summary
Most fixed-dose combination and co-packaged versions of previously approved antiretroviral HIV therapies are unlikely to require user fees under the President's $15 bil. Emergency Plan for AIDS Relief, according to a 1draft guidance released April 15
You may also be interested in...
FDA Collection Of 505(b)(2) User Fees Misguided – WLF Paper
FDA should only assess user fees on 505(b)(2) applications that make changes to the Indications & Usage section of labeling, according to a recent backgrounder from the Washington Legal Foundation
FDA Collection Of 505(b)(2) User Fees Misguided – WLF Paper
FDA should only assess user fees on 505(b)(2) applications that make changes to the Indications & Usage section of labeling, according to a recent backgrounder from the Washington Legal Foundation
AIDS Drug Combos Still Moving Slowly After FDA Guidance
GlaxoSmithKline and Boehringer Ingelheim are in discussions with FDA on a Combivir/Viramune co-package submission after signing a "letter of intent" to develop the product